Skip to content

HTFL HTFL Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Edwards Lifesciences logo
Edwards LifesciencesEW
$6.5M+6.6%
ITG
Integer HoldingsITGR

Other financials

Income statement

See full
Revenue$52.6M+41.3%
Gross profit$42.2M+50.9%
Operating income-$29.5M-68.6%
Net income-$27.4M+15.4%
EPS (diluted)-$0.32+93.9%

Balance sheet

See full
Cash & equivalents$24.4M-78.7%
Total debt$26.3M
Total equity$285.7M+132%
Total assets$344.0M

Cash flow

See full
Operating cash flow-$30.1M-129%
CapEx$1.9M+71.6%
Free cash flow-$32.0M-124%

Valuation

See full
Market cap$2.97B
Enterprise value$2.98B
P/S15.5×

Profitability

See full
Gross margin78.1%+2.4pp
Operating margin-39.7%-4.8pp
Net margin-58.4%-12.1pp
FCF margin-40.1%-2.4pp

Returns & leverage

See full
Return on equity37.1%
Debt / equity0.1×
Current ratio5.6×

Where this comes from

Reported directly by HTFL in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: HTFL’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about HTFL's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is HTFL's operating lease right-of-use asset amortization?
HTFL (HTFL) reported operating lease right-of-use asset amortization of $1.01M in Q1 2026.
How has HTFL's operating lease right-of-use asset amortization changed year-over-year?
HTFL's operating lease right-of-use asset amortization increased by 39.6% year-over-year, from $724K to $1.01M.
What is the long-term trend for HTFL's operating lease right-of-use asset amortization?
Over 2 years (2023 to 2025), HTFL's operating lease right-of-use asset amortization has grown at a 4.1% compound annual growth rate (CAGR), from $2.89M to $3.13M.